Méndez-Sánchez N, Zamora-Valdés D, Vásquez-Fernández F, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 279-280
Archivo PDF: 96.22 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in hispanics in the United States. Arch Intern Med 2007; 167: 1983-9.

2. Sistema Nacional de Información en Salud (SINAIS). [Main causes of general mortality 2005]. http://sinais.salud.gob.mx/mortalidad/mortalidad.htm.

3. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-5.

4. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.

5. Mendez-Sanchez N, Sanchez-Castillo CP, Villa AR, Madrigal H, Merino B, Garcia E, Lopez P, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 66-71.

6. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54.

7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.

8. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, Valencia ME. Effects of traditional and western 1. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in hispanics in the United States. Arch Intern Med 2007; 167: 1983-9.

9. ASCO. Plenary top 5. Oncology 2007; 21: 896.